Prenetics Q1 Revenue Grows 333.7% but Misses Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2026
0mins
Source: seekingalpha
- Revenue Performance: Prenetics reported Q1 revenue of $36 million, reflecting a staggering year-over-year growth of 333.7%, yet it fell short of expectations by $1.9 million, indicating volatility in market demand.
- IM8 Revenue Growth: The IM8 segment generated $33.8 million, up 23.1% from $27.4 million in Q4 2025, showcasing the product line's ongoing growth potential, although market competition remains a concern.
- 2026 Guidance Upgrade: The company raised its full-year 2026 IM8 revenue guidance to between $190 million and $210 million, up from the previous range of $180 million to $200 million, reflecting management's confidence in future performance.
- Financial Health: As of March 31, 2026, Prenetics maintained a strong, debt-free balance sheet with cash and cash equivalents of $56 million and net current assets of $111.7 million, demonstrating financial flexibility for business expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRE
About PRE
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Prenetics (PRE) Q1 2026 Earnings Call Transcript
See More
Prenetics Q1 Revenue Grows 333.7% but Misses Expectations
- Revenue Performance: Prenetics reported Q1 revenue of $36 million, reflecting a staggering year-over-year growth of 333.7%, yet it fell short of expectations by $1.9 million, indicating volatility in market demand.
- IM8 Revenue Growth: The IM8 segment generated $33.8 million, up 23.1% from $27.4 million in Q4 2025, showcasing the product line's ongoing growth potential, although market competition remains a concern.
- 2026 Guidance Upgrade: The company raised its full-year 2026 IM8 revenue guidance to between $190 million and $210 million, up from the previous range of $180 million to $200 million, reflecting management's confidence in future performance.
- Financial Health: As of March 31, 2026, Prenetics maintained a strong, debt-free balance sheet with cash and cash equivalents of $56 million and net current assets of $111.7 million, demonstrating financial flexibility for business expansion.
See More
Prenetics to Release Q1 2026 Financial Results on May 14
- Earnings Release Schedule: Prenetics Global Limited will announce its Q1 2026 financial results before market open on May 14, 2026, providing critical data to assess the company's performance.
- Conference Call Details: On the same day at 10:00 a.m. Eastern Time, Prenetics will hold an earnings conference call to discuss the financial results in detail, featuring a Q&A session with analysts to enhance investor engagement.
- IM8 Brand Achievements: IM8, as Prenetics' flagship brand, has rapidly ascended in the consumer health sector, surpassing $100 million in annualized recurring revenue within just 11 months, indicating strong market demand and brand recognition.
- Global Market Reach: IM8 is now sold in over 40 countries, further solidifying its leadership position in the premium daily nutrition market through science-backed formulations and global brand partnerships.
See More
Prenetics Forms Strategic Partnership with Inter Miami CF
- Exclusive Partnership: Prenetics has entered a multi-year agreement with Inter Miami CF, making IM8 the club's official health supplements partner, marking the first time the club has taken an equity stake in a brand partner, indicating strong confidence in IM8.
- Integration into Daily Routines: IM8's core products will be embedded into the daily training and recovery routines of Inter Miami CF players, enhancing athlete performance and health, thereby solidifying IM8's credibility within the professional sports ecosystem.
- Global Market Expansion: The partnership grants IM8 international rights across 40+ countries, leveraging Inter Miami's global brand influence to significantly boost brand awareness and penetrate key growth markets.
- Financial Growth Outlook: Since its launch in December 2024, IM8 has surpassed $100 million in annualized recurring revenue within just 11 months, with projections for 2026 revenues between $180 million and $200 million, reflecting strong market demand and growth potential.
See More
Giannis Becomes First NBA Athlete Shareholder in NASDAQ Health Brand
- Strategic Partnership: Giannis Antetokounmpo has formed a global partnership with Prenetics, becoming a Global Partner and the first NBA athlete shareholder in IM8, demonstrating his long-term commitment to the brand and expected to drive IM8's global market expansion.
- Revenue Growth Potential: Since its launch in December 2024, IM8 has achieved $100 million in annualized recurring revenue within just 11 months, with projections to reach $180 to $200 million in 2026, showcasing its rapid growth potential in the supplement industry.
- Market Coverage Expansion: With over 35 million social media followers, particularly strong in the U.S., Europe, Africa, and Asia, Giannis's influence aligns perfectly with IM8's global expansion strategy, likely opening new market opportunities for the brand.
- Enhanced Brand Credibility: Collaborations with top athletes like Giannis bolster IM8's cross-sport credibility, and with zero debt and approximately $160 million in liquidity, IM8 is positioned to build a competitive edge in the consumer health sector.
See More
Prenetics Approves $40 Million Share Repurchase Program
- Share Repurchase Program: Prenetics Global Limited's Board of Directors has approved a share repurchase program of up to $40 million, set to be executed over the next 12 months, aimed at enhancing shareholder value and boosting market confidence.
- Insider Share Purchases: The executive leadership team has purchased approximately $1.3 million in shares between February 23 and 27, 2026, including about $750,000 by CEO Danny Yeung, demonstrating strong confidence in the company's future prospects.
- Significant Total Investment: Combined with $1.45 million in purchases made after the November 2025 earnings release, executives have invested approximately $2.75 million in Prenetics shares, reflecting a solid belief in the company's long-term value.
- Strong Stock Performance: Currently, Prenetics shares are trading at $16.23 on Nasdaq, up $1.16 or 7.33% from the previous day, indicating a positive market reaction to the company's repurchase announcement.
See More
Prenetics (PRE) Q1 2026 Earnings Call Transcript
See More
Prenetics Q1 Revenue Grows 333.7% but Misses Expectations
- Revenue Performance: Prenetics reported Q1 revenue of $36 million, reflecting a staggering year-over-year growth of 333.7%, yet it fell short of expectations by $1.9 million, indicating volatility in market demand.
- IM8 Revenue Growth: The IM8 segment generated $33.8 million, up 23.1% from $27.4 million in Q4 2025, showcasing the product line's ongoing growth potential, although market competition remains a concern.
- 2026 Guidance Upgrade: The company raised its full-year 2026 IM8 revenue guidance to between $190 million and $210 million, up from the previous range of $180 million to $200 million, reflecting management's confidence in future performance.
- Financial Health: As of March 31, 2026, Prenetics maintained a strong, debt-free balance sheet with cash and cash equivalents of $56 million and net current assets of $111.7 million, demonstrating financial flexibility for business expansion.
See More
Prenetics to Release Q1 2026 Financial Results on May 14
- Earnings Release Schedule: Prenetics Global Limited will announce its Q1 2026 financial results before market open on May 14, 2026, providing critical data to assess the company's performance.
- Conference Call Details: On the same day at 10:00 a.m. Eastern Time, Prenetics will hold an earnings conference call to discuss the financial results in detail, featuring a Q&A session with analysts to enhance investor engagement.
- IM8 Brand Achievements: IM8, as Prenetics' flagship brand, has rapidly ascended in the consumer health sector, surpassing $100 million in annualized recurring revenue within just 11 months, indicating strong market demand and brand recognition.
- Global Market Reach: IM8 is now sold in over 40 countries, further solidifying its leadership position in the premium daily nutrition market through science-backed formulations and global brand partnerships.
See More
Prenetics Forms Strategic Partnership with Inter Miami CF
- Exclusive Partnership: Prenetics has entered a multi-year agreement with Inter Miami CF, making IM8 the club's official health supplements partner, marking the first time the club has taken an equity stake in a brand partner, indicating strong confidence in IM8.
- Integration into Daily Routines: IM8's core products will be embedded into the daily training and recovery routines of Inter Miami CF players, enhancing athlete performance and health, thereby solidifying IM8's credibility within the professional sports ecosystem.
- Global Market Expansion: The partnership grants IM8 international rights across 40+ countries, leveraging Inter Miami's global brand influence to significantly boost brand awareness and penetrate key growth markets.
- Financial Growth Outlook: Since its launch in December 2024, IM8 has surpassed $100 million in annualized recurring revenue within just 11 months, with projections for 2026 revenues between $180 million and $200 million, reflecting strong market demand and growth potential.
See More
Giannis Becomes First NBA Athlete Shareholder in NASDAQ Health Brand
- Strategic Partnership: Giannis Antetokounmpo has formed a global partnership with Prenetics, becoming a Global Partner and the first NBA athlete shareholder in IM8, demonstrating his long-term commitment to the brand and expected to drive IM8's global market expansion.
- Revenue Growth Potential: Since its launch in December 2024, IM8 has achieved $100 million in annualized recurring revenue within just 11 months, with projections to reach $180 to $200 million in 2026, showcasing its rapid growth potential in the supplement industry.
- Market Coverage Expansion: With over 35 million social media followers, particularly strong in the U.S., Europe, Africa, and Asia, Giannis's influence aligns perfectly with IM8's global expansion strategy, likely opening new market opportunities for the brand.
- Enhanced Brand Credibility: Collaborations with top athletes like Giannis bolster IM8's cross-sport credibility, and with zero debt and approximately $160 million in liquidity, IM8 is positioned to build a competitive edge in the consumer health sector.
See More
Prenetics Approves $40 Million Share Repurchase Program
- Share Repurchase Program: Prenetics Global Limited's Board of Directors has approved a share repurchase program of up to $40 million, set to be executed over the next 12 months, aimed at enhancing shareholder value and boosting market confidence.
- Insider Share Purchases: The executive leadership team has purchased approximately $1.3 million in shares between February 23 and 27, 2026, including about $750,000 by CEO Danny Yeung, demonstrating strong confidence in the company's future prospects.
- Significant Total Investment: Combined with $1.45 million in purchases made after the November 2025 earnings release, executives have invested approximately $2.75 million in Prenetics shares, reflecting a solid belief in the company's long-term value.
- Strong Stock Performance: Currently, Prenetics shares are trading at $16.23 on Nasdaq, up $1.16 or 7.33% from the previous day, indicating a positive market reaction to the company's repurchase announcement.
See More
